The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension

Angiogenesis is critically involved in the development of liver fibrosis, portal hypertension (PHT) and hepatocellular carcinoma (HCC). Regorafenib is a novel second-line therapy for HCC, but might also be beneficial in fibrosis and PHT even in absence of HCC. This study investigated the effects of regorafenib in experimental models without HCC. Fibrosis ( and ), inflammation, liver damage (aminotransferases), angiogenesis (matrigel implantation) and systemic and portal hemodynamics were assessed in different mouse and rat models (bile duct ligation, CCl , partial portal vein ligation) after acute and chronic treatment with regorafenib. Long-term treatment with regorafenib improved portal hypertension most likely due to blunted angiogenesis, without affecting fibrosis progression or regression. Interestingly, acute administration of regorafenib also ameliorated portal hemodynamics. Although regorafenib treatment led to hepatotoxic side effects in long-term treated fibrotic animals, in partial portal vein ligated rats, no liver toxicity due to regorafenib was observed. Regorafenib might be especially suitable as therapy in patients with PHT and preserved liver function.